Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in italy of 297 sporadic cases

American Journal of Gastroenterology

Volumn 105, Issue 6, 2010, Pages 1421-1429

  Zerbi, Alessandro ^a   Falconi, Massimo ^b   Rindi, Guido ^c   Fave, Gianfranco Delle ^d   Tomassetti, Paola ^e   Pasquali, Claudio ^f   Capitanio, Vanessa ^a   Boninsegna, Letizia ^b   Di Carlo, Valerio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CORTICOTROPIN; ENOLASE; GASTRIN; INSULIN; SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; ITALY; LAPAROSCOPY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SOMATOSTATINOMA; SURGICAL MORTALITY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, ISLET CELL; FEMALE; HUMANS; INSULINOMA; ITALY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES;

EID: 77953233381     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.747     Document Type: Article

References (53)

1. Halfdanarson TR, Rubin J, Farnell MB et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008; 15: 409-427
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492
3. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
4. La Rosa S, Klersy C, Uccella S et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40: 30-40.
5. de Herder WW, O'Toole D, Rindi G et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine tumors part 1-stomach, duodenum and pancreas. Neuroendocrinology 2006; 84: 151-216.
6. Kl ö ppel G, Couvelard A, Perren A et al. ENETS guidelines for the standards of care in patients with neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratifi cation. Neuroendocrinology 2009; 90: 162-166
7. Vagefi PA, Razo O, Deshpande V et al. Evolvine patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms. Arch Surg 2007; 142: 347-354
8. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141: 765-770
9. Bajetta E, Ferrari L, Procopio G et al. Effi cacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002; 13: 614-621
10. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12: 111-114
11. Zeng XJ, Zhong SX, Zhu Y et al. Insulinoma: 31 years of tumor localization and excision. J Surg Oncol 1988; 39: 274-278
12. Hirshberg B, Cochran C, Skarulis MC et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005; 104: 264-272
13. Heitz PU, Komminoth P, Perren A et al. WHO histological classifi cation of tumours of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz PU et al. (eds). Pathology and Genetic of Tumours of Endocrine Organs, 1st edn, IARC Press: Lyon, France, 2007; 31: 1677-1682
14. Lepage C, Bouvier AM, Phelip JM et al. Incidence and management of malignant digestive endocrine tumours in a well defi ned French population. Gut 2004; 53: 549-553
15. Eriksson B, O'berg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical fi ndings in a prospective study of 84 patients. Acta Oncologica 1989; 28: 373-377
16. Halfdanarson T, Rabe KG, Rubin J et al. Pancreatic neuroendocrine tumors (PNETS): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19: 1727-1733
17. Balzano G, Zerbi A, Capretti G et al. Eff ect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg 2008; 95: 357-362
18. van Heek NT, Kuhlmann KF, Scholten RJ et al. Hospital volume and mortality aft er pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 2005; 242: 781-788
19. Broder LE, Carter SK. Pancreatic islet cell carcinoma, I: clinical features of 52 patients. Ann Intern Med 1973; 79: 101-107
20. Kent RB III, van Heerden JA, Weiland LH. Nonfunctioning islet cell neoplasms. Ann Surg 1981; 193: 185-190
21. Phan GQ, Yeo CJ, Hruban RH et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998; 2: 472-482
22. Lo CY, van Heerden JA, Th ompson GB et al. Islet cell carcinoma of the pancreas. World J Surg 1996; 20: 878-884
23. Madeira I, Terris B, Voss M et al. Prognostic factors in patients wiThendocrine tumours of the duodenopancreatic area. Gut 1996; 43: 422-427
24. Hochwald SN, Zee S, Conlon KC et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20: 2633-2642
25. Chu QD, Hill HC, Douglass HO Jr et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-862
26. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-1092
27. Tomassetti P, Campana D, Piscitelli L et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16: 1806-1810
28. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2003; 120: 139-161
29. Ekeblad S, Skogseid B, Dunder K et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803
30. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Archiv 1996; 429: 323-333
31. Broughan TA, Leslie JD, Soto JM et al. Pancreatic islet cell tumors. Surgery 1986; 99: 671-678
32. Sarmiento JM, Farnell MB, Que FG et al. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg 2002; 26: 1267-1271
33. White TJ, Edney JA, Th ompson JS et al. Is there a prognostic diff erence between functional and nonfunctional islet cell tumors? Am J Surg 1994; 168: 627-630
34. Jarufe NP, Coldham C, Orug T et al. Neuroendocrine tumours of the pancreas: predictors of survival aft er surgical treatment. Dig Surg 2005; 22: 157-162
35. Th ompson GB, van Heerden JA, Grant CS et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988; 104: 1011-1017
36. Venkatesh S, Ordonez NG, Ajani J et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 1990; 65: 354-357
37. Pape UF, B ö hmig M, Berndt U et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German Referral Center. Ann N Y Acad Sci 2004; 1014: 222-233
38. Norton JA, Kivlen M, Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859-866
39. Hellman P, Andersson M, Rastad J et al. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000; 24: 1353-1360
40. Schurr PG, Strate T, Rese K et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007; 245: 273-281
41. Cubilla AL, Hajdu SI. Islet cell carcinoma of the pancreas. Arch Pathol 1975; 99: 204-207
42. Piani C, Franchi GM, Cappelletti C et al. Cytological Ki67 in pancreatic endocrine tumours: an opportunity for pre-operative grading. Endocr Relat Cancer 2008; 15: 175-181
43. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773
44. Mabrut JY, Fernandez-Cruz L, Azagra JS et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137: 597-605.
45. Falconi M, Plockinger U, Kwekkeboom DJ et al. Well-diff erentiated pancreatic non-functioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211.
46. Crippa S, Bassi C, Warshaw AL et al. Middle pancreatectomy: indications, operative and long-term results. Ann Surg 2007; 246: 69-76.
47. Aranha GV, Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg 2005; 189: 223-228
48. Balzano G, Zerbi A, Veronesi P et al. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg 2003; 20: 506-510
49. Evans DB, Skibber JM, Lee JE et al. Non-functioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175-1181
50. Solorzano CC, Lee JE, Pisters PW et al. Non-functioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085
51. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver; a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.
52. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when it is indicated? Cancer Control 2008; 15: 314-321
53. Bettini R, Mantovani W, Boninsegna L et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009; 41: 49-55.